{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:11:18Z","timestamp":1788865878454,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare UK","doi-asserted-by":"publisher","award":["ISS#222487"],"award-info":[{"award-number":["ISS#222487"]}],"id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ijantimicag.2026.107909","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:07:48Z","timestamp":1783379268000},"page":"107909","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["CABO\u2013CHANCE study: A real-life world study of cabotegravir plus rilpivirine long-acting intramuscular in ART-experienced people with HIV"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6394-5728","authenticated-orcid":false,"given":"Carmen","family":"Hidalgo-Tenorio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Garc\u00eda-Aguilera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7073-5211","authenticated-orcid":false,"given":"Ignacio De Los","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Ruiz-Sancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"L\u00f3pez-Lirola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1345-4901","authenticated-orcid":false,"given":"Alberto","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Bernal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onofre","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Sorni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Garc\u00eda-Oca\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Sanjoaqu\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4268-0150","authenticated-orcid":false,"given":"Jose Ramon","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coral","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2026.107909_bib0001","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(13)61809-7","article-title":"The end of aids: HIV infection as a chronic disease","volume":"382","author":"Deeks","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/v11030200","article-title":"Immune activation, inflammation, and Non-AIDS Co-morbidities in HIV-infected patients under long-term ART","volume":"11","author":"Zicari","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0003","first-page":"220","article-title":"Nuke-sparing regimens for the long-term care of HIV infection","volume":"17","author":"Pasquau","year":"2015","journal-title":"AIDS Rev"},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0004","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","volume":"71","author":"Van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.ijantimicag.2026.107909_bib0005","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/cid\/ciac130","volume":"76","author":"Llibre","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0006","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000016813","article-title":"DOLAMA study: effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients","volume":"98","author":"Hidalgo-Tenorio","year":"2019","journal-title":"Medicine"},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(19)30149-3","article-title":"Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies","volume":"6","author":"Aboud","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0008","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.3390\/v14122626","article-title":"Rildo: real-world multicenter study on the effectiveness and safety of single-tablet regimen of dolutegravir plus rilpivirine in treatment-experienced people living with HIV","volume":"14","author":"Hidalgo-Tenorio","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0009","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0010","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1177\/1060028021995586","article-title":"Cabotegravir-rilpivirine: the first complete long-acting injectable regimen for the treatment of HIV-1 infection","volume":"55","author":"Durham","year":"2021","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0011","unstructured":"ONUSIDA. Programa conjunto de Las Naciones Unidas Sobre El VIH\/Sida. https:\/\/www.unaids.org."},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0012","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"396","author":"Overton","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0013","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/s12879-022-07243-3","article-title":"Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection","volume":"22","author":"Chounta","year":"2022","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0014","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/jama.2024.24543","article-title":"Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the International Antiviral Society\u2013USA Panel","volume":"333","author":"Gandhi","year":"2025","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ijantimicag.2026.107909_bib0015","first-page":"18","article-title":"Major revision version 13.0 of the European","volume":"27","author":"Ambrosioni","year":"2026","journal-title":"AIDS Clinical Society guidelines 2025. HIV Med"},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0016","unstructured":"Documento de consenso de GeSIDA\/Divisi\u00f3n de Control de VIH ITS Hepatitis virales y Tuberculosis del Ministerio de Sanidad respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualizaci\u00f3n enero 2025). https:\/\/gesida-seimc.org\/guias-clinicas\/."},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0017","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1093\/cid\/ciae557","article-title":"Long-acting cabotegravir plus rilpivirine in people with HIV with adherence challenges and viremia: current data and future directions","volume":"80","author":"Davis","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0018","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1007\/s40121-023-00890-2","article-title":"Cabotegravir + rilpivirine long-acting injections for HIV treatment in the US: real world data from the OPERA cohort","volume":"12","author":"Sension","year":"2023","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0019","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S2352-3018(20)30340-4","article-title":"Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study","volume":"8","author":"Orkin","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0020","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1093\/jac\/dkaf246","article-title":"Long-acting cabotegravir and rilpivirine for the treatment of people with HIV: current landscape and challenges ahead","volume":"80","author":"Buz\u00f3n-Mart\u00edn","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0021","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40258-017-0310-5","article-title":"EQ-5D and the EuroQol Group: past, present and future","volume":"15","author":"Devlin","year":"2017","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0022","first-page":"57","article-title":"Intention to treat: once randomized, always analyzed","volume":"23","author":"Wertz","year":"1995","journal-title":"Clin Aphasiol"},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0023","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c2697","article-title":"Modified intention to treat reporting in randomised controlled trials: systematic review","volume":"340","author":"Abraha","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0024","unstructured":"Day S. Analysis Issues, ITT, Post-Hoc, and Subgroups. Johns Hopkins University. 2008. [last accessed on 2010 Jan 17]. Available from: http:\/\/ocw.jhsph.edu\/courses\/BiostatMedicalProductRegulation\/biomed_lec7_day.pdf."},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0025","first-page":"81","article-title":"How much should I weigh? Quetelet\u00b4s equation, upper weight limits, and BMI prime","volume":"70","author":"Gadzik","year":"2006","journal-title":"Conn Med"},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0026","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/S0895-4356(01)00449-8","article-title":"Development and validation of a self-completed HIV symptom index","volume":"54","author":"Justice","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0027","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/1477-7525-11-164","article-title":"Patient reported outcome instruments used in clinical trials of HIV-infected adults on NNRTI-based therapy: a 10-year review","volume":"11","author":"Simpson","year":"2013","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0028","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/jac\/dkaf184","article-title":"Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir\/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort","volume":"80","author":"Gagliardini","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0029","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1093\/jac\/dkaf281","article-title":"A multicentre real-life prospective cohort study on effectiveness, durability and safety of long-acting injectable cabotegravir and rilpivirine in northern Italy: the LONGITUDE study","volume":"80","author":"Mazzitelli","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0030","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.70068","article-title":"Comparable real-world effectiveness between switches to cabotegravir + rilpivirine long-acting or modern daily oral regimens in the United States: an OPERA cohort study","volume":"28","author":"Hsu","year":"2025","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0031","series-title":"Real-world effectiveness and tolerability of cabotegravir + rilpivirine long-acting in people living with HIV-1: a meta-analysis of real-world evidence. eP103","author":"Orkin","year":"2025"},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0032","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3390\/pathogens14070633","article-title":"CD4\/CD8 ratio increase in female living with HIV switching to cabotegravir-rilpivirine: a real-life 24 weeks evaluation","volume":"14","author":"Spampinato","year":"2025","journal-title":"Pathogens"},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0033","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1097\/QAD.0000000000003984","article-title":"CD4+\/CD8+ improvement after switch from a second-generation integrase inhibitor regimen to long-acting cabotegravir and rilpivirine","volume":"38","author":"Muccini","year":"2024","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155100","article-title":"Relevance of interleukin-6 and D-dimer for serious non-AIDS morbidity and death among HIV-positive adults on suppressive antiretroviral therapy","volume":"11","author":"Grund","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0035","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae326","article-title":"One year of long-acting cabotegravir and rilpivirine in people with human immunodeficiency virus and long exposure to antiretroviral therapy: data from the SCohoLART study","volume":"11","author":"Muccini","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0036","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/infdis\/jiw173","article-title":"Interleukin 6 is a stronger predictor of clinical events than high-sensitivity C-reactive protein or D-dimer during HIV infection","volume":"214","author":"Borges","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0037","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.3390\/v17081108","article-title":"Safety, tolerability, and metabolic effects of long-acting cabotegravir and rilpivirine in HIV care: a comprehensive review","volume":"17","author":"Bottanelli","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.ijantimicag.2026.107909_bib0038","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/hiv.70058","article-title":"Patient-reported outcomes in clinical trials assessing the effectiveness of cabotegravir + rilpivirine long-acting injections as antiretroviral therapy: a systematic review","volume":"26","author":"Vinay","year":"2025","journal-title":"HIV Med"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926001962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926001962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:47:51Z","timestamp":1788864471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857926001962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0924857926001962"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107909","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CABO\u2013CHANCE study: A real-life world study of cabotegravir plus rilpivirine long-acting intramuscular in ART-experienced people with HIV","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107909","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107909"}}